Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
MONTREAL, Jan. 03, 2018 -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, at 5:00 p.m. PT at the Westin St. Francis in San Francisco.
A webcast of the presentation will be available in the Investor Relations section of the company's website at www.clementiapharma.com. A replay of the webcast will be available for 30 days following the presentation.
About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.
Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.
+1-514-940-1080
Chelcie Lister
THRUST Investor Relations
+1-910-777-3049
